Catherine Benziger MD MPH FAHA FACC
@drbenzigerheart.bsky.social
Non-invasive Cardiologist | clinical trialist | medical director of heart & vascular research, Essentia Health | associate professor, UMN Med School | public health expert | lipids, hypertension, cardiometabolic | runner, triathlete
Pinned
Ready for an awesome day @ahascience.bsky.social #AHA24
Reposted by Catherine Benziger MD MPH FAHA FACC
Heart attacks remain a leading global challenge, and prevention is key.
Women As One presents a webcast, sponsored by @amgen.bsky.social, bridging patient stories with clinical insights on LDL-C & heart health.
Watch here: womenasone.org/resou...
#WomensHealth #WomenInCardiology
Women As One presents a webcast, sponsored by @amgen.bsky.social, bridging patient stories with clinical insights on LDL-C & heart health.
Watch here: womenasone.org/resou...
#WomensHealth #WomenInCardiology
November 21, 2025 at 3:00 PM
Heart attacks remain a leading global challenge, and prevention is key.
Women As One presents a webcast, sponsored by @amgen.bsky.social, bridging patient stories with clinical insights on LDL-C & heart health.
Watch here: womenasone.org/resou...
#WomensHealth #WomenInCardiology
Women As One presents a webcast, sponsored by @amgen.bsky.social, bridging patient stories with clinical insights on LDL-C & heart health.
Watch here: womenasone.org/resou...
#WomensHealth #WomenInCardiology
Congratulations to the WARRIOR investigators and patients who participated! ✅High risk patients - 1 in 6 readmitted
✅Need to understand mechanisms in INOCA
✅Hard to enroll, hard to retain, underpowered neutral trial
#ACC25 @accintouch.bsky.social
✅Need to understand mechanisms in INOCA
✅Hard to enroll, hard to retain, underpowered neutral trial
#ACC25 @accintouch.bsky.social
March 31, 2025 at 4:10 PM
Congratulations to the WARRIOR investigators and patients who participated! ✅High risk patients - 1 in 6 readmitted
✅Need to understand mechanisms in INOCA
✅Hard to enroll, hard to retain, underpowered neutral trial
#ACC25 @accintouch.bsky.social
✅Need to understand mechanisms in INOCA
✅Hard to enroll, hard to retain, underpowered neutral trial
#ACC25 @accintouch.bsky.social
Julia Harris: Etiology of cardiac arrest in popular film and treatment is misleading and doesn't follow guidelines.
#ACC25 @accintouch.bsky.social
#ACC25 @accintouch.bsky.social
March 31, 2025 at 2:29 PM
Julia Harris: Etiology of cardiac arrest in popular film and treatment is misleading and doesn't follow guidelines.
#ACC25 @accintouch.bsky.social
#ACC25 @accintouch.bsky.social
Reposted by Catherine Benziger MD MPH FAHA FACC
Standing room only. Amazing debate on screening: CAC and separately Lpa, are we here for Universal screening?
don’t stop believing 🔥❤️❤️🔥
#CAC #knowlpa #knowfh #coronarydisease @accintouch.bsky.social @drbenzigerheart.bsky.social #physicianassociate #pasgobeyond #patientshealthfirst #pasdothat
don’t stop believing 🔥❤️❤️🔥
#CAC #knowlpa #knowfh #coronarydisease @accintouch.bsky.social @drbenzigerheart.bsky.social #physicianassociate #pasgobeyond #patientshealthfirst #pasdothat
March 30, 2025 at 4:31 PM
Standing room only. Amazing debate on screening: CAC and separately Lpa, are we here for Universal screening?
don’t stop believing 🔥❤️❤️🔥
#CAC #knowlpa #knowfh #coronarydisease @accintouch.bsky.social @drbenzigerheart.bsky.social #physicianassociate #pasgobeyond #patientshealthfirst #pasdothat
don’t stop believing 🔥❤️❤️🔥
#CAC #knowlpa #knowfh #coronarydisease @accintouch.bsky.social @drbenzigerheart.bsky.social #physicianassociate #pasgobeyond #patientshealthfirst #pasdothat
Reposted by Catherine Benziger MD MPH FAHA FACC
The use of an SGLT2 inhibitor drug improved outcomes in patients undergoing TAVI (transcatheter aortic valve implantation). A randomized, placebo-controilled trial of 620 patients with high risk
www.nejm.org/doi/full/10....
#ACC25 @nejm.org
www.nejm.org/doi/full/10....
#ACC25 @nejm.org
March 29, 2025 at 6:39 PM
The use of an SGLT2 inhibitor drug improved outcomes in patients undergoing TAVI (transcatheter aortic valve implantation). A randomized, placebo-controilled trial of 620 patients with high risk
www.nejm.org/doi/full/10....
#ACC25 @nejm.org
www.nejm.org/doi/full/10....
#ACC25 @nejm.org
Reposted by Catherine Benziger MD MPH FAHA FACC
New @nejm.org #ACC25
The global impact of 5 cardiovascular risk factors (BP, cholesterol, obesity, diabetes, smoking) on life expectancy in men and women
www.nejm.org/doi/full/10.1056/NEJMoa2415879
The global impact of 5 cardiovascular risk factors (BP, cholesterol, obesity, diabetes, smoking) on life expectancy in men and women
www.nejm.org/doi/full/10.1056/NEJMoa2415879
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates | NEJM
Five risk factors account for approximately 50% of the global burden of cardiovascular
disease. How the presence or absence of classic risk factors affects lifetime estimates
of cardiovascular dise...
www.nejm.org
March 30, 2025 at 10:00 PM
New @nejm.org #ACC25
The global impact of 5 cardiovascular risk factors (BP, cholesterol, obesity, diabetes, smoking) on life expectancy in men and women
www.nejm.org/doi/full/10.1056/NEJMoa2415879
The global impact of 5 cardiovascular risk factors (BP, cholesterol, obesity, diabetes, smoking) on life expectancy in men and women
www.nejm.org/doi/full/10.1056/NEJMoa2415879
Reposted by Catherine Benziger MD MPH FAHA FACC
Dr. Nissen presents #ALPACA assessing siRNA in ⬇️ Lp(a) Lepodisiran
♥️400 mg dose: 95% ⬇️, sustained 180 days but still effects after at 540 days
♥️ Large ⬇️ in Lp(a)
♥️ ApoB ⬇️ by 15%
♥️ safety favorable: 1 withdrew in placebo
#ACC25 #CVPrev
@nejm.org
📎 www.nejm.org/doi/full/10....
♥️400 mg dose: 95% ⬇️, sustained 180 days but still effects after at 540 days
♥️ Large ⬇️ in Lp(a)
♥️ ApoB ⬇️ by 15%
♥️ safety favorable: 1 withdrew in placebo
#ACC25 #CVPrev
@nejm.org
📎 www.nejm.org/doi/full/10....
March 30, 2025 at 11:35 PM
Dr. Nissen presents #ALPACA assessing siRNA in ⬇️ Lp(a) Lepodisiran
♥️400 mg dose: 95% ⬇️, sustained 180 days but still effects after at 540 days
♥️ Large ⬇️ in Lp(a)
♥️ ApoB ⬇️ by 15%
♥️ safety favorable: 1 withdrew in placebo
#ACC25 #CVPrev
@nejm.org
📎 www.nejm.org/doi/full/10....
♥️400 mg dose: 95% ⬇️, sustained 180 days but still effects after at 540 days
♥️ Large ⬇️ in Lp(a)
♥️ ApoB ⬇️ by 15%
♥️ safety favorable: 1 withdrew in placebo
#ACC25 #CVPrev
@nejm.org
📎 www.nejm.org/doi/full/10....
Dr. Victor Dzau:
Future of #CVD care is going to be evolving rapidly over the next century:
❤️ Emphasis on prevention
❤️ Equitable access and affordable
❤️ Mission-based innovation
❤️ Develop national priorities
Need governance to oversee innovation, ensure ethics
#acc25
@accintouch.bsky.social
Future of #CVD care is going to be evolving rapidly over the next century:
❤️ Emphasis on prevention
❤️ Equitable access and affordable
❤️ Mission-based innovation
❤️ Develop national priorities
Need governance to oversee innovation, ensure ethics
#acc25
@accintouch.bsky.social
March 30, 2025 at 9:24 PM
Dr. Victor Dzau:
Future of #CVD care is going to be evolving rapidly over the next century:
❤️ Emphasis on prevention
❤️ Equitable access and affordable
❤️ Mission-based innovation
❤️ Develop national priorities
Need governance to oversee innovation, ensure ethics
#acc25
@accintouch.bsky.social
Future of #CVD care is going to be evolving rapidly over the next century:
❤️ Emphasis on prevention
❤️ Equitable access and affordable
❤️ Mission-based innovation
❤️ Develop national priorities
Need governance to oversee innovation, ensure ethics
#acc25
@accintouch.bsky.social
Dr. Victor Dzau:
How do we improve #cvd with rising #obesity?
✅Start with 1° and 2° #cvprev
✅Primordial prevention
@accintouch.bsky.social #acc25
How do we improve #cvd with rising #obesity?
✅Start with 1° and 2° #cvprev
✅Primordial prevention
@accintouch.bsky.social #acc25
March 30, 2025 at 9:11 PM
Dr. Victor Dzau:
How do we improve #cvd with rising #obesity?
✅Start with 1° and 2° #cvprev
✅Primordial prevention
@accintouch.bsky.social #acc25
How do we improve #cvd with rising #obesity?
✅Start with 1° and 2° #cvprev
✅Primordial prevention
@accintouch.bsky.social #acc25
Reposted by Catherine Benziger MD MPH FAHA FACC
Dr. Amy Sarma:
Who needs monogenic genetic testing for #SCAD ?
✅Men
✅Aortic aneurysm
✅Family history
✅SCAD pt wanting pregnancy
Otherwise likely polygenic
@accintouch.bsky.social #acc25
#cvprev
Who needs monogenic genetic testing for #SCAD ?
✅Men
✅Aortic aneurysm
✅Family history
✅SCAD pt wanting pregnancy
Otherwise likely polygenic
@accintouch.bsky.social #acc25
#cvprev
March 30, 2025 at 7:01 PM
Dr. Amy Sarma:
Who needs monogenic genetic testing for #SCAD ?
✅Men
✅Aortic aneurysm
✅Family history
✅SCAD pt wanting pregnancy
Otherwise likely polygenic
@accintouch.bsky.social #acc25
#cvprev
Who needs monogenic genetic testing for #SCAD ?
✅Men
✅Aortic aneurysm
✅Family history
✅SCAD pt wanting pregnancy
Otherwise likely polygenic
@accintouch.bsky.social #acc25
#cvprev
Hey ladies! Come to theater 1 now to hear about why we need more women leaders in clinical trials #acc25
@accintouch.bsky.social
@accintouch.bsky.social
March 30, 2025 at 6:04 PM
Hey ladies! Come to theater 1 now to hear about why we need more women leaders in clinical trials #acc25
@accintouch.bsky.social
@accintouch.bsky.social
Is menopause a disease? No! It's part of aging and occurs in 1/2 the pop.
Vasomotor symptoms are real
✅assess #cvd risk across the lifespan
✅Need outcome studies of HRT and GLP1RA by risk
✅ask♀️about all risk factors including pregnancy and cardiometabolic risks
@accintouch.bsky.social #acc25
Vasomotor symptoms are real
✅assess #cvd risk across the lifespan
✅Need outcome studies of HRT and GLP1RA by risk
✅ask♀️about all risk factors including pregnancy and cardiometabolic risks
@accintouch.bsky.social #acc25
March 30, 2025 at 5:28 PM
Is menopause a disease? No! It's part of aging and occurs in 1/2 the pop.
Vasomotor symptoms are real
✅assess #cvd risk across the lifespan
✅Need outcome studies of HRT and GLP1RA by risk
✅ask♀️about all risk factors including pregnancy and cardiometabolic risks
@accintouch.bsky.social #acc25
Vasomotor symptoms are real
✅assess #cvd risk across the lifespan
✅Need outcome studies of HRT and GLP1RA by risk
✅ask♀️about all risk factors including pregnancy and cardiometabolic risks
@accintouch.bsky.social #acc25
Excited to see the results of WARRIOR study. It was a tremendous effort from so many sites (including Essentia where I was site PI) with so many women with INOCA. More to come! @accintouch.bsky.social #acc25 #cvd
March 30, 2025 at 5:01 PM
Excited to see the results of WARRIOR study. It was a tremendous effort from so many sites (including Essentia where I was site PI) with so many women with INOCA. More to come! @accintouch.bsky.social #acc25 #cvd
Reposted by Catherine Benziger MD MPH FAHA FACC
BHF #protecttavi
#ACC25 #LBCT
❓Does routine use of Sentinel in TAVI reduce stroke
💥PROTECT TAVI demonstrates NO difference in Tx vs Control group in Stroke rate: currently would not use this in routine clinical practice
@nejm.org
www.nejm.org/doi/full/10....
#ACC25 #LBCT
❓Does routine use of Sentinel in TAVI reduce stroke
💥PROTECT TAVI demonstrates NO difference in Tx vs Control group in Stroke rate: currently would not use this in routine clinical practice
@nejm.org
www.nejm.org/doi/full/10....
March 30, 2025 at 3:49 PM
BHF #protecttavi
#ACC25 #LBCT
❓Does routine use of Sentinel in TAVI reduce stroke
💥PROTECT TAVI demonstrates NO difference in Tx vs Control group in Stroke rate: currently would not use this in routine clinical practice
@nejm.org
www.nejm.org/doi/full/10....
#ACC25 #LBCT
❓Does routine use of Sentinel in TAVI reduce stroke
💥PROTECT TAVI demonstrates NO difference in Tx vs Control group in Stroke rate: currently would not use this in routine clinical practice
@nejm.org
www.nejm.org/doi/full/10....
Reposted by Catherine Benziger MD MPH FAHA FACC
In a late-breaking clinical trial, Dr. John Forrest from @yaleschoolofmed.bsky.social reports that low-risk patients with AS treated with #TAVR had similar rates of mortality and stroke at 5 years compared to those treated with surgery jacc.org/doi/10.1016/...
#JACC #ACC25 #vhdAS #SAVR #CardioSky
#JACC #ACC25 #vhdAS #SAVR #CardioSky
March 30, 2025 at 4:34 PM
In a late-breaking clinical trial, Dr. John Forrest from @yaleschoolofmed.bsky.social reports that low-risk patients with AS treated with #TAVR had similar rates of mortality and stroke at 5 years compared to those treated with surgery jacc.org/doi/10.1016/...
#JACC #ACC25 #vhdAS #SAVR #CardioSky
#JACC #ACC25 #vhdAS #SAVR #CardioSky
Excited to be one of 71 sites in the WARRIOR study, results presented by Eileen Handberg @accintouch.bsky.social #acc25
✅ 17% event rate over 5 years
✅ No significant difference between intensive medical therapy and usually care
✅ 17% event rate over 5 years
✅ No significant difference between intensive medical therapy and usually care
March 29, 2025 at 2:46 PM
Excited to be one of 71 sites in the WARRIOR study, results presented by Eileen Handberg @accintouch.bsky.social #acc25
✅ 17% event rate over 5 years
✅ No significant difference between intensive medical therapy and usually care
✅ 17% event rate over 5 years
✅ No significant difference between intensive medical therapy and usually care
Great start to #acc25 with the @accintouch.bsky.social 75th anniversary gala at the Field
March 29, 2025 at 12:59 PM
Great start to #acc25 with the @accintouch.bsky.social 75th anniversary gala at the Field
This breaks my 💔
Johns Hopkins to Cut More Than 2,000 Workers Funded by Federal Aid www.nytimes.com/2025/03/13/u...
Johns Hopkins to Cut More Than 2,000 Workers Funded by Federal Aid www.nytimes.com/2025/03/13/u...
Federal Cuts Prompt Johns Hopkins to Cut More Than 2,000 Workers
The university, a leader in scientific research, has been hard hit by the Trump administration’s cuts, which will slash at least $800 million from its budget.
www.nytimes.com
March 15, 2025 at 11:51 AM
This breaks my 💔
Johns Hopkins to Cut More Than 2,000 Workers Funded by Federal Aid www.nytimes.com/2025/03/13/u...
Johns Hopkins to Cut More Than 2,000 Workers Funded by Federal Aid www.nytimes.com/2025/03/13/u...
Reposted by Catherine Benziger MD MPH FAHA FACC
Association of Prepregnancy Cardiometabolic Health With Hypertensive Disorders of Pregnancy Among Historically Underrepresented Groups in United States
#CardioObstetrics #CardioSky #MedSky #OBGYN #JAHA
@ahajournals.bsky.social
@erinmichos.bsky.social
www.ahajournals.org/doi/10.1161/...
#CardioObstetrics #CardioSky #MedSky #OBGYN #JAHA
@ahajournals.bsky.social
@erinmichos.bsky.social
www.ahajournals.org/doi/10.1161/...
Association of Prepregnancy Cardiometabolic Health With Hypertensive Disorders of Pregnancy Among Historically Underrepresented Groups in the United States | Journal of the American Heart Association
www.ahajournals.org
November 24, 2024 at 5:08 AM
Association of Prepregnancy Cardiometabolic Health With Hypertensive Disorders of Pregnancy Among Historically Underrepresented Groups in United States
#CardioObstetrics #CardioSky #MedSky #OBGYN #JAHA
@ahajournals.bsky.social
@erinmichos.bsky.social
www.ahajournals.org/doi/10.1161/...
#CardioObstetrics #CardioSky #MedSky #OBGYN #JAHA
@ahajournals.bsky.social
@erinmichos.bsky.social
www.ahajournals.org/doi/10.1161/...
Reposted by Catherine Benziger MD MPH FAHA FACC
In people with T2D, effects of GLP1-RA on CV, kidney & mortality outcomes are consistent irrespective of SGLT2i
Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation
www.ahajournals.org/doi/10.1161/...
Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation
www.ahajournals.org/doi/10.1161/...
November 27, 2024 at 8:54 PM
In people with T2D, effects of GLP1-RA on CV, kidney & mortality outcomes are consistent irrespective of SGLT2i
Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation
www.ahajournals.org/doi/10.1161/...
Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation
www.ahajournals.org/doi/10.1161/...
Reposted by Catherine Benziger MD MPH FAHA FACC
Assessing Accuracy of CVD Prediction Using Female-Specific Risk Factors in Women Aged 45-69 Yrs in UK Biobank Study
#CardioSky #MedSky #Circulation
@ahajournals.bsky.social @ahascience.bsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social
www.ahajournals.org/doi/10.1161/...
#CardioSky #MedSky #Circulation
@ahajournals.bsky.social @ahascience.bsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social
www.ahajournals.org/doi/10.1161/...
December 8, 2024 at 6:59 PM
Assessing Accuracy of CVD Prediction Using Female-Specific Risk Factors in Women Aged 45-69 Yrs in UK Biobank Study
#CardioSky #MedSky #Circulation
@ahajournals.bsky.social @ahascience.bsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social
www.ahajournals.org/doi/10.1161/...
#CardioSky #MedSky #Circulation
@ahajournals.bsky.social @ahascience.bsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social
www.ahajournals.org/doi/10.1161/...
Great discussion on the current state of #statin and #dementia in older adults research at the #Preventabletrial investigator meeting
December 10, 2024 at 4:33 PM
Great discussion on the current state of #statin and #dementia in older adults research at the #Preventabletrial investigator meeting
Reposted by Catherine Benziger MD MPH FAHA FACC
With more layers of data, our ability to predict a person's risk of heart disease is getting better and better
acpjournals.org/doi/10.7326/...
[adding in social determinants of health, lifestyle, genomics, and other data] @annalsofim.bsky.social
December 9, 2024 at 10:28 PM
With more layers of data, our ability to predict a person's risk of heart disease is getting better and better
acpjournals.org/doi/10.7326/...
[adding in social determinants of health, lifestyle, genomics, and other data] @annalsofim.bsky.social